ALPMF

Stock Details

ALPMF is Astellas Pharma Inc.'s stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 14.43$. Average daily volumn in 3 months 2.42k. Market cap 25.54B

Stock symbol : ALPMF. Exchange : Other OTC. Currency : USD
Lastest price : 14.02$. Total volume : 1.00. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Astellas Pharma Inc. (ALPMF)

Last Price

14.02$

Change

0.00

Volume

1.00


Previous Close	14.02
Open	14.02
Day Range	14.02-14.02
Bid	0.00 x N/A
Ask	0.00 x N/A
Volume	1
Average Volume	2.42k


Market Cap	25.54B
Beta	0.55
52 Week Range	12.77-16.71
Trailing P/E	24.60
Foward P/E	N/A
Dividend (Yield %)	3.36%
Ex-Dividend Date	2023-03-30

Financial Details

According to Astellas Pharma Inc.'s financial reports the company's revenue in 2022 were 1.3T an increase(0%) over the years 2021 revenue that were of 1.25T. In 2022 the company's total earnings were 124.09B while total earnings in 2021 were 120.59B( +3.33%).

Loading ...

Organization

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adre... nergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Market Cap:

25.54B

Revenue:

1.3T

Total Assets:

2.33T

Total Cash:

315.99B

News about "Astellas Pharma Inc."

Astellas Pharma

Source from : Forbes - 11 days ago

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation ...See details»

Astellas Pharma Board Approves Changes Of Management Structure

Source from : Nasdaq - 1 month ago

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that its board approved changes of its Representative Director, President and chief executive officer and its management structure.See details»

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

Source from : Yahoo Finance - 28 days ago

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug ...See details»

Astellas : Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal

Source from : Business Insider - 7 days ago

(RTTNews) - Astellas Pharma Inc. (ALPMY) announced positive results from the Phase 3 China ARCHES study of Xtandi (enzalutamide) plus androgen deprivation therapy in men with metastatic hormone ...See details»

Astellas’ phase 3 China ARCHES study of Xtandi plus ADT in men with mHSPC meets primary endpoint

Source from : Pharmabiz - 6 days ago

Astellas Pharma Inc. announced positive topline results from the phase 3 China ARCHES study of Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive ...See details»

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

Source from : Benzinga.com - 12 days ago

TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and the Blood and ...See details»

Results for Astellas’ non-hormonal menopause drug published in The Lancet

Source from : PMLiVE - 6 days ago

Astellas Pharma’s investigational non-hormonal compound, fezolinetant, has been associated with significant improvements in moderate to severe vasomotor symptoms (VMS) due to menopause, according to ...See details»

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug

Source from : YAHOO!Finance - 4 days ago

Pfizer Inc (NYSE: PFE) and Astellas Pharma Inc (OTC: ALPMY) released topline results from the Phase 3 EMBARK trial evaluating Xtandi (enzalutamide) in non-metastatic hormone-sensitive prostate cancer.See details»

Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally ...

Source from : newsroom.businesswire.com - 11 days ago

TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq: SGEN ...See details»

Astellas’ Phase III trial of gilteritinib disappoints

Source from : The Pharma Letter - 12 days ago

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) today announced disappointing top-line results from the Phase III MORPHO clinical trial evaluating gilteritinib as a maintenance ...See details»

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

Source from : Medindia - 7 days ago

About AstellasAstellas Pharma Inc. is a pharmaceutical company conducting ... Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE ...See details»

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

Source from : Morningstar - 29 days ago

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug ...See details»

Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

Source from : Benzinga.com - 7 days ago

TOKYO, March 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the Phase 3 China ARCHES ...See details»